Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity

Drugs of Today

Volumn 47, Issue 12, 2011, Pages 903-914

  Bays, Harold E ^a   Gadde, K M ^b  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECONGESTIVE AGENT; GUANETHIDINE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; TOPIRAMATE; VALPROIC ACID;

ANOREXIA; ANXIETY; ATTENTION DISTURBANCE; BLOOD PRESSURE; BRAIN DISEASE; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DEPRESSION; DIAPHORESIS; DIZZINESS; DOSE RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHORIA; EUPHORIA; FATIGUE; HEADACHE; HEART PALPITATION; HUMAN; HYPERAMMONEMIA; HYPERHIDROSIS; IMPOTENCE; INSOMNIA; IRRITABILITY; LIBIDO; MEMORY DISORDER; METABOLIC ACIDOSIS; METABOLIC DISORDER; MIGRAINE; MONOTHERAPY; MOOD CHANGE; NEPHROLITHIASIS; NERVOUSNESS; OBESITY; PARESTHESIA; PSYCHOMOTOR DISORDER; PSYCHOSIS; RESTLESSNESS; REVIEW; SEIZURE; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TASTE; TASTE DISORDER; TREMOR; UNPLEASANT TASTE; URTICARIA; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALS; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; CHEMISTRY, PHARMACEUTICAL; DRUG APPROVAL; DRUG COMBINATIONS; FRUCTOSE; HUMANS; OBESITY; PHENTERMINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84856567446     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.12.1718738     Document Type: Review

References (73)

1. Bays, H.E. "Sick fat," metabolic disease, and atherosclerosis. Am J Med 2009, 122(1, Suppl.): S26-37.
2. Bays, H.E. Adiposopathy: Is "sick fat" a cardiovascular disease? J Am College Cardiol 2011, 57(25): 2461-73.
3. Bays, H., Ballantyne, C. Adiposopathy: why do adiposity and obesity cause metabolic disease? Fut Lipidol 2006, 1(4): 389-420.
4. Bays, H., Blonde, L., Rosenson, R. Adiposopathy: How do diet, exercise, weight loss and drug therapies improve metabolic disease? Expert Rev Cardiovasc Ther 2006, 4(6): 871-95. (Pubitemid 46017525)
5. Varady, K.A., Tussing, L., Bhutani, S., Braunschweig, C.L. Degree of weight loss required to improve adipokine concentrations and decrease fat cell size in severely obese women. Metabolism 2009, 58(8): 1096-101.
6. Bays, H.E. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease. Expert Rev Cardiovasc Ther 2009, 7(11): 1429-45.
7. Rothman, R.B. Treatment of obesity with "combination" pharmacotherapy. Am J Ther 2010, 17(6): 596-603.
8. Bays, H. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. Expert Rev Cardiovasc Ther 2010, 8(12): 1777-801.
9. Colman, E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med 2005, 143(5): 380-5. (Pubitemid 41266610)
10. Beydoun, A. Monotherapy trials of new antiepileptic drugs. Epilepsia 1997, 38(Suppl. 9): S21-31.
11. Bays, H.E., Rodbard, R.W., Schorr, A.B., González-Campoy, J.M. Adiposopathy: Treating pathogenic adipose tissue to reduce cardiovascular disease risk. Curr Treat Options Cardiovasc Med 2007, 9(4): 259-71. (Pubitemid 47181092)
12. Hendricks, E.J., Rothman, R.B., Greenway, F.L. How physician obesity specialists use drugs to treat obesity. Obesity (Silver Spring) 2009, 17(9): 1730-5.
13. Coyne, T.C. Phentermine-resin or salt-there are differences. Arch Intern Med 1997, 157(20): 2381-2.
14. Bays, H.E. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Expert Rev Cardiovasc Ther 2011, 9(3): 265-77.
15. U.S. Food and Drug Administration. Joint Meeting of the Peripheral and Central Nervous Drugs Advisory Committee and the Psychopharmacologic Drugs Advisory Committee Briefing Information. http://www.fda.gov/ohrms/dockets/ac/08/ briefing/2008-4372b1-00-index.html Accessed October 8, 2011.
16. Arana, A., Wentworth, C.E., Yuso-Mateos, J.L., Arellano, F.M. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med 2010, 363(6): 542-51.
17. Patorno, E., Bohn, R.L., Wahl, P.M., Avorn, J. et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010, 303(14): 1401-9.
18. Gadde, K.M., Allison, D.B., Ryan, D.H., Peterson, C.A. et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377(9774): 1341-52.
19. Food and Drug Administration. Advisory Committee meeting for phentermine/topiramate (Qnexa). Division of Metabolism and Endocrinology Products (DMEP) Office of Drug Evaluation II Center for Drug Evaluation & Research, U.S. Food & Drug Administration 2010. http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM218824.pdf. Accessed September 8, 2011.
20. FDA accepts New Drug Application filing for Qnexa [news release]. VIVUS, Inc., November 3, 2011. http://ir.vivus.com/releasedetail.cfm?ReleaseID=620724. Accessed Decmber 14, 2011.
21. VIVUS files European Marketing Authorization Application for QNEXA® in the treatment of obesity [news release]. VIVUS, Inc., December 20, 2010. http://ir.vivus.com/releasedetail.cfm?ReleaseID=537928. Accessed December 14, 2011.
22. Hirsch, J., Mackintosh, R.M., Aronne, L.J. The effects of drugs used to treat obesity on the autonomic nervous system. Obes Res 2000, 8(3): 227-33.
23. Ulus, I.H., Maher, T.J., Wurtman, R.J. Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol 2000, 59(12): 1611-21. (Pubitemid 30229896)
24. Rothman, R.B. Is phentermine an inhibitor of monoamine oxidase? A critical appraisal. Synapse 1999, 32(2): 141-5. (Pubitemid 29230144)
25. Rothman, R.B. Retraction and apology: Is phentermine an inhibitor of monoamine oxidase? Synapse 1999, 33(1): 81. (Pubitemid 29269952)
26. Kilpatrick, I.C., Traut, M., Heal, D.J. Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release. Int J Obes Relat Metab Disord 2001, 25(10): 1454-8. (Pubitemid 32977861)
27. Rader, W.A., Steelman, G.M., Westman, E.C. Clinical experience using appetite suppressants and SSRIs. J Okla State Med Assoc 2008, 101(8): 180-1.
28. Kim, K.K., Cho, H.J., Kang, H.C., Youn, B.B. et al. Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. Yonsei Med J 2006, 47(5): 614-25. (Pubitemid 44697292)
29. Aronne, L.J., Halseth, A.E., Burns, C.M., Miller, S. et al. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity (Silver Spring) 2010, 18(9): 1739-46.
30. Maryanoff, B.E. Sugar sulfamates for seizure control: discovery and development of topiramate, a structurally unique antiepileptic drug. Curr Top Med Chem 2009, 9(11): 1049-62.
31. Braga, M.F., Roniadou-Anderjaska, V., Li, H., Rogawski, M.A. Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons. J Pharmacol Exp Ther 2009, 330(2): 558-66.
32. Khazaal, Y., Zullino, D.F. Topiramate-induced weight loss is possibly due to the blockade of conditioned and automatic processes. Eur J Clin Pharmacol 2007, 63(9): 891-2. (Pubitemid 47237895)
33. McElroy, S.L., Arnold, L.M., Shapira, N.A., Keck, P.E., Jr. et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003, 160(2): 255-261. (Pubitemid 41110450)
34. Khazaal, Y., Zullino, D.F. Topiramate in the treatment of compulsive sexual behavior: case report. BMC Psychiatry 2006, 622.
35. Turenius, C.I., Htut, M.M., Prodon, D.A., Ebersole, P.L. et al. GABA(A) receptors in the lateral hypothalamus as mediators of satiety and body weight regulation. Brain Res 2009, 1262: 16-24.
36. Husum, H., Van, K.D., Termeer, E., Bolwig, G. et al. Topiramate normalizes hippocampal NPY-LI in flinders sensitive line 'depressed' rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects. Neuropsycho-pharmacology 2003, 28(7): 1292-9. (Pubitemid 41070899)
37. Heiman, M.L., Statnick, M.A. Galanin-like peptide functions more like leptin than like galanin. Endocrinology 2003, 144(11): 4707-8. (Pubitemid 37378380)
38. Schutt, M., Brinkhoff, J., Drenckhan, M., Lehnert, H. et al. Weight reducing and metabolic effects of topiramate in patients with migraine - an observational study. Exp Clin Endocrinol Diabetes 2010, 118(7): 449-52.
39. Theisen, F.M., Beyenburg, S., Gebhardt, S., Kluge, M. et al. A prospective study of body weight and serum leptin levels in patients treated with topiramate. Clin Neuropharmacol 2008, 31(4): 226-30.
40. Tremblay, A., Chaput, J.P. About the appetite-related effects of topiramate. Eur J Clin Pharmacol 2007, 63(9): 893.
41. Winum, J.Y., Scozzafava, A., Montero, J.L., Supuran, C.T. Sulfamates and their therapeutic potential. Med Res Rev 2005, 25(2): 186-228.
42. Poulsen, S.A., Wilkinson, B.L., Innocenti, A., Vullo, D. et al. Inhibition of human mitochondrial carbonic anhydrases VA and VB with para-(4-phenyltriazole-1-yl)-benzenesulfonamide derivatives. Bioorg Med Chem Lett 2008, 18(16): 4624-7.
43. Vullo, D., Franchi, M., Gallori, E., Antel, J. et al. Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. J Med Chem 2004, 47(5): 1272-9. (Pubitemid 38229129)
44. Richard, D., Ferland, J., Lalonde, J., Samson, P. et al. Influence of topiramate in the regulation of energy balance. Nutrition 2000, 16(10): 961-6.
45. Wilkes, J.J., Nguyen, M. T., Bandyopadhyay, G. K., Nelson, E. et al. Topiramate treatment causes skeletal muscle insulin sensitization and increased Acrp30 secretion in high-fat-fed male Wistar rats. Am J Physiol Endocrinol Metab 2005, 289(6): E1015-22. (Pubitemid 43671051)
46. Kadowaki, T., Yamauchi, T., Kubota, N., Hara, K. et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116(7): 1784-92. (Pubitemid 44033298)
47. Dridi, S., Taouis, M. Adiponectin and energy homeostasis: consensus and controversy. J Nutr Biochem 2009, 20(11): 831-9.
48. Silberstein, S.D., Neto, W., Schmitt, J., Jacobs, D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004, 61(4): 490-5. (Pubitemid 38923736)
49. Picard, F., Deshaies, Y., Lalonde, J., Samson, P. et al. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res 2000, 8(9): 656-63.
50. Richard, D., Picard, F., Lemieux, C., Lalonde, J. et al. The effects of topiramate and sex hormones on energy balance of male and female rats. Int J Obes Relat Metab Disord 2002, 26(3): 344-53. (Pubitemid 34226159)
51. Tremblay, A., Chaput, J.P., Berube-Parent, S., Prud'homme, D. et al. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension. Eur J Clin Pharmacol 2007, 63(2): 123-34. (Pubitemid 46147053)
52. Lachkar, Y., Bouassida, W. Drug-induced acute angle closure glaucoma. Curr Opin Ophthalmol 2007, 18(2): 129-33.
53. Lee, G.C., Tam, C.P., Nesh-Meyer, H.V., Myers, J.S. et al. Bilateral angle closure glaucoma induced by sulphonamide-derived medications. Clin Exp Ophthalmol 2007, 35(1): 55-8. (Pubitemid 46195929)
54. Astrup, A., Toubro, S. Topiramate: a new potential pharmacological treatment for obesity. Obes Res 2004, 12(Suppl. 1): 67S-173S.
55. Epstein, D.L., Grant, W.M. Carbonic anhydrase inhibitor side effects. Serum chemical analysis. Arch Ophthalmol 1977, 95(8): 1378-2.
56. Mirza, N., Marson, A.G., Pirmohamed, M. Effect of topiramate on acid-base balance: extent, mechanism and effects. Br J Clin Pharmacol 2009, 68(5): 655-61.
57. Vega, D., Maalouf, N.M., Sakhaee, K. Increased propensity for calcium phosphate kidney stones with topiramate use. Expert Opin Drug Saf 2007, 6(5): 547-57. (Pubitemid 351308213)
58. Galicia, S.C., Lewis, S.L., Metman, L.V. Severe topiramate-associated hyperthermia resulting in persistent neurological dysfunction. Clin Neuropharmacol 2005, 28(2): 94-5. (Pubitemid 40471885)
59. Vahedi, K., Taupin, P., Djomby, R., El-Amrani, M. et al. Efficacy and tolerability of acetazolamide in migraine prophylaxis: a randomised placebo-controlled trial. J Neurol 2002, 249(2): 206-11. (Pubitemid 34143477)
60. Leombruni, P., Lavagnino, L., Fassino, S. Treatment of obese patients with binge eating disorder using topiramate: a review. Neuropsychiatr Dis Treat 2009, 5385-92.
61. Shorvon, S.D. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996, 37(Suppl. 2): S18-22. (Pubitemid 26192219)
62. Ben-Menachem, E., Axelsen, M., Johanson, E.H., Stagge, A. et al. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003, 11(4): 556-62. (Pubitemid 41202417)
63. Wilding, J., Van, G.L., Rissanen, A., Vercruysse, F. et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 2004, 28(11): 1399-410. (Pubitemid 39481843)
64. Stenlof, K., Rossner, S., Vercruysse, F., Kumar, A. et al. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab 2007, 9(3): 360-8. (Pubitemid 46502056)
65. Bray, G.A., Hollander, P., Klein, S., Kushner, R. et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003, 11(6): 722-33. (Pubitemid 41151598)
66. Astrup, A., Caterson, I., Zelissen, P., Guy-Grand, B. et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004, 12(10): 1658-69. (Pubitemid 41132475)
67. Rosenstock, J., Hollander, P., Gadde, K. M., Sun, X. et al. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care 2007, 30(6): 1480-6. (Pubitemid 46871158)
68. Toplak, H., Hamann, A., Moore, R., Masson, E. et al. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int J Obes (Lond) 2007, 31(1): 138-46. (Pubitemid 46006027)
69. Tonstad, S., Tykarski, A., Weissgarten, J., Ivleva, A. et al. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol 2005, 96(2): 243-51.
70. Wilkes, J.J., Nelson, E., Osborne, M., Demarest, K.T. et al. Topiramate is an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats. Am J Physiol Endocrinol Metab 2005, 288(3): E617-24.
71. Bays, H.E. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004, 12(8): 1197-211. (Pubitemid 41137461)
72. Khanna, V., Arumugam, S., Roy, S., Mittra, S. et al. Topiramate and type 2 diabetes: an old wine in a new bottle. Expert Opin Ther Targets 2008, 12(1): 81-90. (Pubitemid 351247164)
73. Eliasson, B., Gudbjornsdottir, S., Cederholm, J., Liang, Y. et al. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. Int J Obes (Lond) 2007, 31(7): 1140-7. (Pubitemid 46987760)